Superworth

Innoviva price to sales ratio INVA

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
3.4×
10-year median
3.7×
Against its 10-year history
36th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.0× to 11.6×
Peer median
2.0×

Innoviva's price to sales ratio is 3.4× as of Oct 23, 2026.

That is below its ten-year median of 3.7×, close to the middle of its last ten years.

Over that time it ranged from 2.0× in Sep 2022 to 11.6× in Feb 2017.

The median for 10 large drugmakers of a similar size is 2.0×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.4×3.4×4.5×
20253.8×2.9×4.3×
20243.1×3.0×3.8×
20233.5×2.2×3.6×
20222.5×2.0×3.7×
20213.2×2.7×4.0×
20203.9×3.2×5.9×
20195.4×4.0×8.0×
20186.9×5.9×9.5×
20178.0×7.1×11.6×
201610.3×9.3×37.6×
201532.2×27.1×138×
2014n/m a value too high to mean anything
201320.1×11.2×23.1×
201211.5×10.9×12.2×

Against its peers

Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.

CompanyPrice to sales ratio
INVAInnoviva3.4×
ANABAnaptysbion/m
PCRXPacira BioSciences1.9×
PAHCPhibro Animal Health1.0×
ANIPANI Pharmaceuticals1.7×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals1.5×
HRMYHarmony Biosciences2.2×
PBHPrestige Consumer Healthcare2.0×
ABUSArbutus Biopharma4.6×
NRIXNurix Therapeutics3.9×
Peer median2.0×

Where Innoviva ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Innoviva

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.